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Heterologous immunity of virus-specific T cells poses a potential barrier to transplantation
tolerance. Cross-reactivity to HLA-A and -B molecules has broadly been described,
whereas responses to allo-HLA-C have remained ill defined. In contrast to the transplant
setting, HLA-C is the only polymorphic HLA molecule expressed by extravillous
trophoblasts at the maternal-fetal interface during pregnancy. Uncontrolled placental viral
infections, accompanied by a pro-inflammatory milieu, can alter the activation status
and stability of effector T cells. Potential cross-reactivity of maternal decidual virus-
specific T cells to fetal allo-HLA-C may thereby have detrimental consequences for the
success of pregnancy. To explore the presence of cross-reactivity to HLA-C and the
other non-classical HLA antigens expressed by trophoblasts, HLA-A and -B-restricted
CD8+ T cells specific for Epstein-Barr virus, Cytomegalovirus, Varicella-Zoster virus, and
Influenza virus were tested against target cells expressing HLA-C, -E, and -G molecules.
An HLA-B∗08:01-restricted EBV-specific T cell clone displayed cross-reactivity against
HLA-C∗01:02. Furthermore, cross-reactivity of HLA-C-restricted virus-specific CD8+ T
cells was observed for HCMV HLA-C∗06:02/TRA CD8+ T cell lines and clones against
HLA-C∗03:02. Collectively, these results demonstrate that cross-reactivity against HLA-C
can occur and thereby may affect pregnancy outcome.
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1. INTRODUCTION
High frequencies of memory T cells against several viruses such as Influenza virus (FLU), Epstein-
Barr virus (EBV), Human Cytomegalovirus (HCMV), and Varicella-Zoster virus (VZV) have been
described in healthy individuals (1–3). Primary infection or reactivation of these viruses can
compromise graft survival after transplantation and during pregnancy result in fetal malformation
and pregnancy complications such as preterm birth and intrauterine growth restriction (4–
7). A significant proportion of virus-specific CD8+ T cells in healthy (non-HLA sensitized)
individuals display alloreactivity against allogeneic human leukocyte antigens (allo-HLA) (8, 9).
This phenomenon, referred to as heterologous immunity, enables the same T-cell receptor (TCR)
to recognize its autologous virus-peptide presenting HLA allele as well as allo-HLA. The avidity of
these cross-reactive T cells for their viral and allogeneic targets depends on the levels of peptide
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presentation (10). Within an individual, an HLA-restricted virus-
specific T cell response can generate several clonotypes that have
different patterns of allo-HLA cross-reactivity (11). Both naïve
and memory T cells show alloreactive potential, though memory
T cells pose a superior threat (12, 13). Their activation threshold
is significantly lower as they have less need for co-stimulation
while their cytotoxic function is enhanced (14, 15). To ensure a
comprehensive immune response to foreign antigens, this high
degree of cross-reactivity is an intrinsic and essential feature of
antigen recognition by T cells, of which allo-HLA cross-reactivity
is an inherent consequence (16).
In the pregnancy setting T cells have a dual role in mediating
tolerance toward the allogeneic fetus and at the same time
responding to infections. During gestation, fetal extravillous
trophoblasts (EVT) deeply invade the maternal tissues (decidua)
where they establish direct contact with the maternal immune
cells. EVT do not express the highly polymorphic HLA-A and -B,
but do express HLA-C, -E, and -G (17, 18). CD8+ T cells present
in the decidua demonstrate a mixed transcriptional profile of T
cell dysfunction, activation and effector function. They are not
permanently suppressed, but maintain the capacity to respond to
proinflammatory occurrences, such as infections (19). Significant
numbers of HLA-A and -B-restricted virus-specific CD8+ T cells
are found in decidual tissue of term pregnancy (20). Furthermore,
in the maternal peripheral blood, cytotoxic T lymphocyte
(CTL) responses to paternal allo-HLA (HLA-A/B) and minor
histocompatibility antigens (mHag) have been detected during
pregnancy (21–23). Thus, maternal CD8+ T cells can respond
to viral, fetal and placental antigens during pregnancy but so
far no evidence exists on the presence of HLA-C-restricted viral
and mHag-specific CD8+ T cells and whether maternal HLA-A
and -B-restricted virus-specific CD8+T cells can cross-react with
fetal HLA antigens, leading to possible pregnancy complications.
Recognition of fetal HLA-C by both B cells and helper T cells
is suggested by the presence of specific HLA-C IgG antibodies
in women with recurrent miscarriages (24). Furthermore, HLA-
C incompatibility is significantly increased in couples with
unexplained recurrent miscarriages when compared to control
subjects (25). In addition, certain combinations of maternal killer
cell immunoglobulin-like receptor (KIR) genotypes, expressed by
decidual NK cells, and fetal HLA-C are associated with pregnancy
complications such as preeclampsia (26). These data indicate
that fetal HLA-C could play a vital role in guiding the maternal
immune response during pregnancy.
Studies on heterologous immunity in transplantation have
focused on the cross-reactivity of HLA-A and -B-restricted virus-
specific CD8+ T cells with allogeneic HLA-A and -B, with less
attention for HLA-C considering its lower cell surface expression
levels when compared to HLA-A and -B (27). In the context of
pregnancy HLA-C is the only polymorphic antigen expressed
on EVT and alloreactivity to HLA-C (and HLA-E and -G) is
therefore unique and highly significant. The importance of HLA-
C incompatibility in pregnancy complications coupled to the
presence of virus-specific CD8+ T cells at the maternal-fetal
interface, led us to investigate whether cross-reactivity of virus-
specific CD8+ T cells against HLA-C, -E and -G is a common
phenomenon in healthy individuals.
2. RESULTS
2.1. Alloreactivity of an EBV B8/FLR CD8+
T Cell Clone 4D5 Against HLA-C∗01:02
To investigate the ability of virus-specific CD8+ T cells to cross-
react with HLA-C, -E, and -G, 29 HLA-A and -B-restricted
human CMV, FLU, VZV, and EBV-specific CD8+ T cell lines
and clones (28) were tested against a panel of single antigen
expressing lines (SALs) expressing HLA-C, -E, and -G alleles
(n = 11) (29, 30). An HLA-A2-restricted EBV-specific CD8+
T cell clone isolated from placental decidua parietalis was also
included (20). The specificities of the isolated virus-specific
CD8+ T cell lines and clones are listed in Table 1. Lack of
IFNγ production revealed that alloreactivity against HLA-C, -E,
and -G is not common Table 2. Nonetheless, one HLA-B∗08:01-
restricted EBV-specific (EBV B8/FLR) T cell clone, 4D5, showed
significant alloreactivity against HLA-C∗01:02 Figure 1A. This T
cell clone was isolated from an HLA-C∗01:02 negative donor.
To corroborate alloreactivity against HLA-C∗01:02, one EBV
B8/FLR T cell line and four T cell clones were stimulated with
a panel of SALs and EBV lymphoblastoid cell lines (EBV-LCLs)
expressing HLA-C∗01:02 and HLA-B∗44:02 alleles for 24 h after
which IFNγ production was measured. Alloreactivity of EBV
B8/FLR T cells against HLA-B∗44:02 is a commonly described
occurrence (31). T cell clone 4D5 reacted against its virus-specific
restriction allele HLA-B∗08:01 loaded with FLR peptide as well
as HLA-C∗01:02 expressed by SALs and EBV-LCLs. Its lower
alloreactivity against the second EBV-LCL donor expressing
heterozygous HLA-C∗01:02 may have been a result of low HLA-
C expression. T cell clone 4D5 did not show alloreactivity against
HLA-B∗44:02 Figure 1B. T cell clone 4B8 (here shown as a
representative example), comprising a different TCR Vα and
Vβ usage than 4D5 Table 3, displayed no alloreactivity against
HLA-C∗01:02 and only cross-reacted with HLA-B∗44:02 when
loaded with the appropriate self-peptide (EEY). The other EBV
B8/FLR CD8+ T cells tested also did not cross-react with HLA-
C∗01:02, but displayed cross-reactivity against HLA-B∗44:02. No
alloreactivity against HLA-E and -G was discerned Figure S1.
Alloreactivity of virus-specific CD8+ T cells can be cell
type or tissue-specific (9, 32). Therefore, to further functionally
TABLE 1 | Specificities of isolated virus-specific CD8+ T cell lines and clones.
Virus HLA Antigen Epitope
HCMV HLA-A*02:01 pp65 (495-503) NLVPMVATV
HCMV HLA-B*35:01 pp65 (123-131) IPSINVHHY
HCMV HLA-C*06:02 pp65 (201-209) TRATKMQVI
HCMV HLA-C*07:02 IE-1 (309-317) CRVLCCYVL
EBV HLA-A*02:01 BMLF1 (280-288) GLCTLVAML
EBV HLA-B*08:01 EBNA-3A (325-333) FLRGRAYGL
EBV HLA-B*35:01 EBNA-3A (458-466) YPLHEQHGM
FLU HLA-A*02:01 IMP (58-66) GILGFVFTL
VZV HLA-A*02:01 IE-62 (593-601) ALWALPHAA
HCMV, human Cytomegalovirus; EBV, Epstein-Barr virus; FLU, Influenza virus; VZV,
Varicella-Zoster virus.
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TABLE 2 | Alloreactivity of virus-specific CD8+ T cell lines and clones against HLA-C, -E, and -G.
Donor Specificity TCR Vβ # T cell
lines/clones
tested
Allo-HLA-C Allo-HLA-E, -G Target
cell (s)
Allo-HLA-C, -E,
-G cross-reactivity
A HCMV A2/NLV 2 2 2 2 SALs No
HCMV A2/NLV 8 3 2 3 SALs No
HCMV A2/NLV 13.1 1 0 1 SALs No
HCMV A2/NLV 5.2 1 0 1 SALs No
HCMV A2/NLV # 9 0 9 SALs No
A HCMV B35/IPS 2 1 0 1 SALs No
HCMV B35/IPS 3 2 2 2 SALs No
HCMV B35/IPS 13.2 2 1 2 SALs No
HCMV B35/IPS 22 1 1 1 SALs No
HCMV B35/IPS * 2 2 2 SALs No
B HCMV B35/IPS 3 3 2 3 SALs No
C HCMV B35/IPS 3 4 2 4 SALs No
A FLU A2/GIL 17 3 2 3 SALs No
FLU A2/GIL 17+18 1 0 1 SALs No
D FLU A2/GIL 17 4 1 4 SALs No
B FLU A2/GIL # 3 2 3 SALs No
E FLU A2/GIL # 2 1 2 SALs No
F FLU A2/GIL # 1 0 1 SALs No
F VZV A2/ALW # 1 1 1 SALs No
G VZV A2/ALW # 1 1 1 SALs No
H EBV B35/YPL 14 1 1 1 SALs No
EBV B35/YPL 21.3 2 2 2 SALs No
EBV B35/YPL * 1 1 1 SALs No
I EBV A2/GLC
(decidua parietalis)
# 1 1 1 SALs No
J EBV B8/FLR 7 2 2 2 SALs, EBV-LCLs No
K EBV B8/FLR (4D5) 3 1 1 1 SALs, EBV-LCLs,
PHA
blasts
HLA-C*01:02
EBV B8/FLR 4 2 2 2 SALs, EBV-LCLs No
L HCMV
C*0702/CRV
6 1 1 1 721.221,
EBV-LCLs
No
M HCMV
C*0602/TRA
13 2 2 2 SALs, EBV-LCLs No
HCMV
C*0602/TRA (1A3,
7A12, 10C1)
28 2 2 2 SALs, EBV-LCLs,
PHA blasts
HLA-C*03:02
Summary
* The TCR Vβ could not be determined with the TCR Vβ kit used. Specificities 9
# Not tested. Donors 13
TCR tested 21
T cell lines/clones
tested against
HLA-C, -E, -G
34
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FIGURE 1 | Alloreactivity of EBV B8/FLR T cell clone 4D5 against
HLA-C*01:02. (A) EBV B8/FLR T cell lines (n = 9; 1A11 shown) and T cell
clones (n = 6; 4D5, clone 1, and clone 19 shown) were stimulated with a panel
of HLA-C expressing SALs after which IFNγ production was measured. EBV
B8/FLR T cell clone 4D5 showed alloreactivity against HLA-C*01:02. (B) One
EBV B8/FLR T cell line and four EBV B8/FLR T cell clones (4B8 and 4D5
shown) were stimulated with a panel of SALs and EBV-LCLs expressing
HLA-B*08:01, HLA-C*01:02, and HLA-B*44:02 alleles after which IFNγ
production was measured. The range of the ELISA standard curve: 5–5120
pg/ml; Ho, homozygous; He, heterozygous. Bars represent duplicate values
with standard deviation of the mean.
validate our results, cytotoxicity of the T cell clones 4D5 and
4B8 was investigated against 51Chromium (51Cr) -labeled human
umbilical vein endothelial cells (HUVECs), SALs (myeloid
origin), EBV-LCLs (B cells) and PHA blasts (T cells) expressing
the recognized allo-HLA-C∗01:02 allele and the virus-specific
restriction allele HLA-B∗08:01 loaded with viral peptide as a
positive control. Target cells expressing no HLA-B∗08:01 and
HLA-C∗01:02 were included as a negative control. The T cell
clones were added to their targets in four effector: target ratios.
Specific lysis of HLA-C∗01:02 expressing SALs, EBV-LCLs and
PHA blasts by T cell clone 4D5 was observed in a ratio-dependent
manner. T cell clone 4D5 was however not lytic against HUVECs
expressing HLA-C∗01:02, presumably the result of the relevant
self-peptide not being expressed by this cell type (33) Figure 2A.
The robust cytolytic response of T cell clone 4D5 against EBV-
LCLs expressing HLA-C∗01:02 was substantially decreased by
addition of an anti-CD8 blocking antibody, while lysis of target
cells expressing the virus-specific restriction allele HLA-B∗08:01
loaded with FLR peptide was not affected, indicating distinct
TCR affinities Figure 2B. No specific lysis by T cell clone 4B8
was observed Figure 2C. Together, these results demonstrate that
alloreactivity of HLA-A and -B-restricted virus-specific CD8+ T
cells against HLA-C can occur and is dependent on CD8.
2.2. Characterization of
HLA-C∗06:02-Restricted HCMV-Specific T
Cell Lines and Clones
HLA-C-restricted virus-specific CD8+ T cells have been
described in the context of HIV infection where they recognize
a highly conserved epitope and in HCMV infection where HLA-
C∗07:02-restricted CD8+ T cells dominate the T cell response
to the immediate-early 1 (IE-1) viral antigen and their levels
increase with age (34–36). Given their high allele frequency
in the population, we set out to isolate HLA-C∗06:02- and
HLA-C∗07:02-restricted HCMV-specific CD8+ T cells (37, 38)
and explore their alloreactivity against HLA-C, -E, and -G.
PBMC of HLA-C∗06:02+HCMV+ donors (n = 10) were stained
with an HLA-C∗06:02 tetramer containing the HCMV TRA
peptide (39) Table 1. From a donor with 15% positivity for
the HLA-C∗06:02/TRA tetramer, CD8+ T cell lines and clones
were generated by sorting tetramer positive CD8+ T cells and
expanding them in vitro Figure 3A; Figure S2. An established
HLA-C∗07:02-restricted HCMV-specific CD8+ T cell clone (LH)
was included in the analysis (35). To examine the functionality
of these HLA-C∗06:02/TRA-restricted HCMV-specific T cell
lines and clones, as well as the HLA-C∗07:02/CRV-restricted
HCMV-specific T cell clone LH, IFNγ production was measured
after 24 h of co-culture with SALs and EBV-LCLs expressing
HLA-C∗06:02 or C∗07:02 loaded with the appropriate viral
peptide. All HLA-C∗06:02-restricted T cell lines and clones, and
the HLA-C∗07:02-restricted clone LH responded against their
virus-specific restriction HLA-allele loaded with viral peptide
Figure 3B. In addition, specific lysis in a ratio-dependent manner
of 51Cr-labeled SALs, 721.221 cells expressing HLA-C∗07:02,
and EBV-LCLs was detected Figure 3C. These results confirmed
functionality of the generatedHLA-C∗06:02-restricted T cell lines
and clones (HCMV C∗06:02/TRA), and the established HLA-
C∗07:02-restricted T cell clone LH (HCMV C∗07:02/CRV).
2.3. Alloreactivity and Cytotoxicity of
HCMV C∗06:02/TRA T Cell Lines Against
HLA-C∗03:02
Next, the HCMVC∗06:02/TRACD8+ T lines and clones (n= 4),
and HCMV C∗07:02/CRV CD8+ T cell clone LH were tested
against a panel of SALs expressing HLA-C, -E, and -G, in
a co-culture system where IFNγ production was assessed.
No alloreactivity was observed in this setting Figures S3A,B.
Subsequently, in a similar manner, alloreactivity against a panel
of EBV-LCLs covering the most common HLA alleles was
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investigated Table 4. Interestingly, two HCMV C∗06:02/TRA T
cell lines cross-reacted with EBV-LCL donor 12 of which T
cell line 1A3 is shown as a representative example Figure 4A.
When comparing the HLA typing of all 20 EBV-LCL donors
in the panel, HLA-C∗03:02 expressed by donor 12 was the only
non-overlapping HLA allele candidate. A SAL expressing HLA-
C∗03:02 is not present in the panel and therefore cross-reactivity
against this allele was not picked up in the initial screening
Figures 3SA,B. A role for HLA class II was ruled out. CD8+ T
cell lines and clones cross-reacting against donor 12 disclosed a
distinct TCR Vα and Vβ usage when compared to CD8+ T cells
showing no alloreactivity Table 3. No alloreactivity of the HCMV
C∗07:02/CRV clone LH was observed Figure 4A.
To further gauge the alloreactivity against HLA-C∗03:02,
HCMV C∗06:02/TRA T cell lines (n= 2) and clones (n= 5) with
the same TCR Vβ usage as the two CD8+ T cell lines that cross-
reacted with cells from donor 12 (and all isolated from an HLA-
C∗03:02 negative donor) were stimulated with EBV-LCLs and
PHA blasts expressing the recognized allo-HLA-C∗03:02 allele.
Target cells expressing the virus-specific restriction allele HLA-
C∗06:02 loaded with viral peptide were included as a positive
control. Alloreactivity against HLA-C∗03:02 was detected for all
HCMV C∗06:02 T cells tested, with substantially more IFNγ
production against EBV-LCLs than against PHA blasts 1 and
2, obtained from two different donors Figure 4B. Differential
HLA expression levels on the cell surface may explain increased
alloreactivity against PHA blast 3 expressing HLA-C∗03:02,
obtained from a third donor Figure S4.
Having identified IFNγ production against allo-HLA-C∗03:02,
HCMV C∗06:02/TRA T cell lines and clones were tested for
cytotoxicity against 51Cr-labeled SALs, EBV-LCLs, and PHA
blasts expressing HLA-C∗03:02. Target cells expressing the virus-
specific restriction allele HLA-C∗06:02 loaded with viral peptide
were included as a positive control. The CD8+ T cell lines
and clone were added to their targets in four effector: target
ratios. Specific lysis of HLA-C∗03:02 expressing target cells was
observed in a ratio-dependent manner Figure 5A. Subsequently,
the T cell lines and clone were incubated with an anti-CD8
blocking antibody prior to co-culture with the 51Cr-labeled target
cells resulting in substantially decreased lysis of target cells
expressing HLA-C∗03:02. A decrease in lysis was not observed
for target cells expressing the virus-specific restriction allele
HLA-C∗06:02 loaded with viral peptide, indicating distinct TCR
affinities Figure 5B. These findings highlight the functionality of
the isolated HCMV C∗06:02/TRA T cell lines and clones and
provide evidence that alloreactivity of HLA-C-restricted virus-
specific CD8+ T cells against HLA-C is a phenomenon that
occurs.
3. DISCUSSION
Alloreactivity of HLA-A and -B-restricted virus-specific CD8+
T cells against HLA-A and -B is common. Eighty percent of
virus-specific T cell lines and 45% of virus-specific T cell clones
disclosed cross-reactivity against allo-HLA molecules (9). Here,
we have shown that alloreactivity of HLA-A and -B-restricted
Frontiers in Immunology | www.frontiersin.org 5 December 2018 | Volume 9 | Article 2880
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FIGURE 2 | EBV B8/FLR T cell clone 4D5 is cytotoxic against HLA-C*01:02. Cytotoxicity of T cell clones 4D5 (A) and 4B8 (C) was tested against 51Cr-labeled
HUVECs, SALs, EBV-LCLs, and PHA blasts expressing the recognized allo-HLA-C*01:02 allele and the virus-specific restriction HLA allele loaded with viral peptide as
a positive control. As a negative control, target cells expressing no HLA-B*0801 and HLA-C*0102 were included. (B) T cell clone 4D5 was incubated with an anti-CD8
blocking antibody prior to co-culture with 51Cr-labeled EBV-LCLs and specific lysis was measured. Bars represent triplicate values with standard deviation of the
mean.
virus-specific CD8+ T cells against HLA-C can also occur.
Amongst the 29 HLA-A and -B-restricted virus-specific T cells
tested, one EBV B8/FLR CD8+ T cell clone 4D5 with distinct
TCR Vα and Vβ usage displayed cross-reactivity and cytotoxicity
against target cells expressing HLA-C∗01:02, indicative of a
more than 10 times lower frequency within the pool of HLA-
A and -B-restricted virus-specific CD8+ T cells tested. This T
cell clone did not reveal the classical described cross-reaction
against HLA-B∗44:02. Our preliminary data suggests that HLA-
C cross-reactivity in HLA-C-restricted virus-specific T cells is
more common. HLA-C∗06:02-restricted HCMV-specific CD8+
T cells were successfully isolated from an HCMV+ donor by
means of HLA-C tetramers and deemed fully functional in
vitro. Alloreactivity of these HCMV C∗06:02/CRV T cell lines
and clones, with distinct TCR Vα and Vβ usage, was observed
against HLA-C∗03:02. This alloreactivity was mediated by IFNγ
production and cytotoxicity. Viral specificity and alloreactivity
are thought to be mediated by the same TCR (9), where in
our setting anti-viral reactivity occurred independent of CD8,
while allo-HLA-C reactivity was CD8 dependent. Differential
recognition of HLA-C on SALs, EBV-LCLs, PHA blasts, and
HUVECs, that did not provoke any alloreactivity, is an indication
that cross-reactivity is determined by endogenous peptide (11)
and supports the anticipation that tissue-specific peptides are
presented and recognized. The nature of the endogenous peptide
presented in HLA-C∗01:02 and HLA-C∗03:02, provoking the
allo-response, is however unknown. Alternatively, expression of
costimulatory and coinhibitorymolecules by virus-specific T cells
may have an influence on T cell signaling and thereby the extent
of the allo-response (40). No alloreactivity against HLA-E and
-G was observed. Our initial screening was against a panel of
SALs expressing most, but not all HLA-C, -E, and -G molecules
and we therefore may have underestimated the allo-response of
virus-specific CD8+ T cells against these HLA alleles.
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FIGURE 3 | Generated HCMV HLA-C*06:02/TRA T cell lines and clones, and the HCMV HLA-C*07:02/CRV T cell clone are cytolytic against their target cells. (A)
FACS plots of HLA-C*06:02/TRA tetramer staining at time of sorting and 2 weeks after expansion of the tetramer-positive CD8+ T cells. (B) Two HCMV C*06:02/TRA
T cell lines (1A3 shown) and two T cell clones, and HCMV C*07:02/CRV T cell clone LH were stimulated with SALs and EBV-LCLs expressing HLA-C*06:02 or
C*07:02 loaded with viral peptide. (C) Cytotoxicity of one HCMV C*06:02/TRA T cell line (1A3 shown) and two T cell clones, and HCMV C*07:02/CRV T cell clone LH
was tested against 51Cr-labeled SALs, 721.221 cells and EBV-LCLs expressing the virus-specific restriction HLA allele alone or loaded with viral peptide. The range of
the ELISA standard curve: 5–5120 pg/ml. Ho, homozygous; He, heterozygous. Bars represent triplicate values with standard deviation of the mean.
Variation of HLA-C expression at the cell surface can be a
result of microRNA binding and discrepancies in exons that
influence the structure of the peptide-binding cleft and the
diversity of peptides bound by HLA-C molecules (27, 41).
Differential expression of HLA-C has an influence on the
ability of CD8+ T cells to mount an immune response. High
expression of HLA-C has been associated with protection against
infections, yet at the same time correlates with autoimmune
disease (42). Nevertheless, when viral peptides are presented
in the HLA-C locus, immune responses are still lower than
to those presented in the HLA-A and -B loci (43). The lower
expression of HLA-C at the cell surface and the differential
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TABLE 4 | HLA class I typing of the EBV-LCL panel.
HLA class I
Panel ID A B C
1 02:01, 32:01 08:01, 44:05 02:02, 07:01/06/18
2 24:02, 33:01 14:02 02:02/32, 08:02/29
3 03:01/22, 29:02/09 07:02/61/114,
44:03/105
07:02, 16:01
4 11:01/43, 33:03/51 18:01/17N, 52:01 07:02, 07:04
5 11:01/33, 30:01/54 13:02, 35:01/42 04:01, 06:02
6 01:01, 26:01 08:01, 49:01 07:01
7 11:01, 31:01 15:01, 57:01 03:03, 06:02/55
8 02:03, 24:02 38:02, 40:01 03:04, 07:02
9 29:02, 31:01 18:01/17N, 58:01 05:01, 07:18/01
10 24:03 51:01 15:02
11 26:01 38:01 12:03
12 24:02, 30:01 51:01, 58:01 01:02, 03:02
13 02:01, 03:01 15:01 03:03
14 68:01, 68:02 44:02/19N, 55:01 03:03, 07:04
15 24:02, 31:01 39:01, 55:01 03:03, 12:03
16 30:01, 68:02 42:01 17:01
17 01:01 41:01 17:01
18 02:01, 11:01 35:01, 44:03 04:01, 16:01
19 02:01, 25:01 18:01/17N/43,
44:02/19N/55
05:01, 12:03
20 24:02, 31:01/119 07:02/294/298,
07:05
07:02, 15:05
immune responses that it triggers when compared to HLA-A
and -B (44) may be an explanation for less frequent alloreactivity
against HLA-C.
We speculate that alloreactivity of virus-specific CD8+ T
cells against HLA-C may play a role in pregnancy complications
where HLA-C is the only polymorphic HLA allele expressed
by EVT. Viral infections of the fetus or the placenta can
lead to severe birth defects or pregnancy loss (5). Viruses are
capable of downregulating surface HLA-A and -B expression
upon infection, while HLA-C expression is spared (45). EVT
also persistently express HLA-C when infected with HCMV
(46). HLA-A and -B-restricted virus-specific CD8+ T cells
are present at the maternal-fetal interface (20) and may be
capable of cross-reacting with HLA-C under certain pro-
inflammatory environmental circumstances and depending on
(allo) peptide expression, thereby jeopardizing the success
of pregnancy. It is yet to be established whether HLA-C-
restricted virus-specific CD8+ T cells are present at the
maternal-fetal interface and if so, whether they are capable of
mounting an immune response. While the presence of anti-
HLA-C IgG antibodies has been described in women with
recurrent miscarriages, the competency of virus-specific CD8+
T cells to cross-react with HLA-C raises the question whether
allo-HLA-C IgG antibodies are the only player in recurrent
miscarriages or whether decidual virus-specific CD8+ T cells
with cross-reactive potential also play their part in pregnancy
complications.
Cross-reactivity of virus-specific CD8+ T cells against HLA-C
can occur and consequently our results lay the foundation for
further investigation into this cross-reactivity in the context
of pregnancy. Future research will focus on isolating virus-
specific CD8+ T cells from the peripheral blood of women
with either a healthy pregnancy or recurrent miscarriage.
Alloreactivity and differences thereof by these virus-specific
CD8+ T cells, obtained after normal pregnancy and miscarriage
cases, against target cells expressing allo-HLA-C, -E, and -G
molecules can then be investigated. Isolating viable HLA-G+
EVT from first trimester and term placentas that express the
correct HLA typing is challenging. Yet, it is important that
allo-HLA reactive CD8+ T cells are tested against primary
EVT expressing allo-HLA-C, as EVT may have protective
mechanisms in place that prevent allo-HLA responses to
ensure a successful pregnancy. A recent study described
aberrant expression of HLA-DR in syncytiotrophoblasts and
syncytiotrophoblast-derived extracellular vesicles (STEVs)
in pre-eclampsia but not control placentae, addressing the
importance of further examining heterologous immunity of not
only decidual CD8+ T cells, but also decidual CD4+ T cells
(47).
Not only in the pregnancy setting has HLA-C disparity been
described as a possible cause of complication. In transplantation,
HLA-C incompatibility has been associated with graft failure
after bone marrow transplantation (48). Furthermore, HLA-C
mismatches were significantly correlated with acute transplant
rejection and increased chronic graft-vs.-host disease (GvHD)
after hematopoietic stem cell transplantation (49, 50). Graft loss
after solid organ transplantation and GvHD after hematopoietic
stem cell transplantation (51) have been associated with
heterologous immunity against allo-HLA-A and -B. The
proven alloreactivity of virus-specific CD8+ T cells against
HLA-C could lead to allo-immune responses and add an
additional barrier to tolerance that requires further assessment
in transplantation.
In conclusion, alloreactivity against HLA-C occurs and may
have pronounced clinical implications in pregnancy, where the
only polymorphic allo-HLA antigen expressed by EVT is HLA-
C. It remains to be established how often this alloreactivity could
lead to the development of pregnancy complications, such as
recurrent miscarriages.
4. MATERIALS AND METHODS
4.1. Preparation of Responder and Target
Cells
Peripheral blood leukocytes were isolated from buffy coats
obtained from healthy blood donors after informed consent,
at Sanquin Blood Supply, the Netherlands. PBMC were
isolated by standard density gradient centrifugation and
cryopreserved until use. Single HLA antigen–transfected K562
cells (SALs) were generated as described previously (52). HLA
typing was performed by sequence-specific oligonucleotide
or sequence-specific primer genotyping at the Department
of Immunohematology and Blood Transfusion, LUMC, the
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FIGURE 4 | Alloreactivity of HCMV C*06:02/TRA T cell lines against HLA-C*03:02. (A) Two HCMV C*06:02/TRA T cell lines (1A3 shown) and two T cell clones (1F12
shown), and HCMV C*07:02/CRV T cell clone LH were stimulated with a panel of EBV-LCLs after which IFNγ production was measured. (B) Three HCMV
C*06:02/TRA T cell lines (1A3 shown) and five T cell clones (10C1 shown) were stimulated with EBV-LCLs and PHA blasts, obtained from two different donors,
expressing the recognized allo-HLA-C*03:02 allele and the virus-specific restriction allele HLA-C*06:02 loaded with viral peptide as a positive control. SALs expressing
HLA-C*06:02 loaded with viral peptide were also included as a positive control. The range of the ELISA standard curve: 5–5120 pg/ml. Bars represent duplicate
values with standard deviation of the mean.
Netherlands. Epstein-Barr virus transformed lymphoblastoid
cell lines (EBV-LCLs) were generated by incubating PBMC
with the supernatant of the EBV-producing marmoset cell
line B95.8 for 1.5 h at 37◦C, and additional culture in
RPMI 1640 Medium (Gibco Life Technologies, Carlsbad, CA)
supplemented with 10% Fetal Calf Serum (FCS; Sigma Aldrich,
St. Louis, Missouri), Penicillin/Streptavidin (Pen/Strep) and L-
glutamine (all from Gibco). The 721.221 cell line expressing
HLA-C∗07:02 was kindly obtained from Professor Anthony
W. Purcell (Monash University; cell line originally made by
the laboratory of Prof. Andrew Brooks at the University of
Melbourne).
Phytohaemagglutinin (PHA) blasts were generated by
incubating PBMC for 8 days in RPMI 1640 Medium, Pen/Strep,
L-glutamine, 15% human serum (HS, Sanquin, Amsterdam,
the Netherlands), IL-2 (60 IU/ml; Novartis, Novartis, Horsham,
UK) and PHA (4 µg/ml; Murex Biotech Ltd, Dartford, UK).
Human umbilical vein endothelial cells (HUVECs) were
cultured in M199 medium supplemented with 10% Newborn
calf Serum (NCS), 1% sodium pyruvate, Pen/Strep (all from
Gibco), 0,1% β-mercaptoethanol (0.05M, Sigma Aldrich), 1%
sodium heparin (400 IE/ml; LUMC, Leiden, the Netherlands),
and bovine purine extract (BPE; 100 µl in 20 ml; Invitrogen,
Carlsbad, CA).
4.2. Generation of Virus-Specific CD8+ T
Cell Lines and Clones
PBMC from EBV+, HCMV+, FLU+, and VZV+ blood donors
were stained with phycoerythrin (PE)-labeled viral tetramers
HCMV HLA-A∗02:01/NLV, HCMV HLA-B∗35:01/IPS, EBV
HLA-A∗02:01/GLC, EBV HLA-B∗08:01/FLR, EBV HLA-
B∗35:01/YPL, FLUHLA-A∗02:01/GIL, VZVHLA-A∗02:01/ALW
(Protein facility, Department of Immunohematology and Blood
Transfusion, LUMC, Leiden, the Netherlands), and an Alexa-
647-labeled viral tetramer HCMV pp65 HLA-C∗06:02/TRA
(NIH Tetramer Core Facility, Emory University, Atlanta, GA)
Table 1. The HCMV HLA-C∗07:02/CRV-specific CD8+ T cell
clone was generated by CRV peptide stimulation of PBMC from
an HCMV+ HLA-C∗07:02+ donor. Additional staining with
conjugated mouse anti-human monoclonal antibodies CD56,
CD14, CD4, CD19 (FITC; BD Biosciences, San Jose, CA), CD45
(PE-Cy5; eBioscience, San Diego, CA), and CD8 (Pacific Orange;
ThermoFisher, Waltham, MA) was performed. When staining
with the HCMV pp65 HLA-C∗06:02/TRA tetramer, CD158
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FIGURE 5 | HCMV C*06:02/TRA T cell lines and clones are cytotoxic against HLA-C*03:02. (A) Cytotoxicity of two HCMV C*06:02/TRA CD8+ T cell lines (1A3
shown) and one CD8+ T cell clone (10C1) was tested against 51Cr-labeled EBV-LCLs and PHA blasts, obtained from three different donors, expressing the
recognized allo-HLA-C*03:02 allele and the virus-specific restriction HLA allele loaded with viral peptide as a positive control. SALs expressing HLA-C*06:02 loaded
with viral peptide were also included as a positive control. (B) The CD8+ T cell lines and clone were incubated with an anti-CD8 blocking antibody prior to co-culture
with target cells and specific lysis was measured. Bars represent triplicate values with standard deviation of the mean.
(KIR2DL1/S1/S3/S5) and CD158b (KIR2DL2/L3) (PE-Cy7;
Biolegend, San Diego, CA) were included in the panel to exclude
binding of CD8+ T cells to the tetramer through KIR (38).
Tetramer-positive CD8+ T cells were purified with FACS sort
based on the expression of CD45+CD8+CD19-CD14-CD56-
CD4-KIR- tetramer+ cells. CD8+ T cell lines were generated
by sorting 10 tetramer-positive cells per round-bottom 96-well
and CD8+ T cell clones by sorting 1 tetramer-positive cell per
round-bottom 96-well, respectively. After sorting, tetramer-
positive CD8+ T cells were expanded in 96-well plates with
irradiated PBMC (4,000 Rad) isolated from buffy coats in
Iscove’s Modified Dulbecco’s Medium (IMDM; Lonza, Basel,
Switzerland) supplemented with Pen/Strep, L-Glutamine, 5%
HS, 5% FCS, PHA (2 µl/ml; Remel, Lenexa, KS), and IL2
(60 IU/ml). TCR Vα and Vβ usage was determined by DNA
sequencing using TCR-specific polymerase chain reaction
primers (53) followed by use of the BigDye R© Terminator
V3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA).
4.3. Cytokine Production Assay
After 8 days of expansion with allogeneic irradiated PBMC,
CD8+ T cell lines and clones (5 x 103) were incubated with
EBV-LCLs and PHA blasts (5 x 104) expressing either self-
HLA, self-HLA loaded with viral peptide (incubation 30 min
at 37◦C; washed thrice), or allo-HLA molecules (duplicate; 96-
wells) in IMDM supplemented with Pen/Strep, L-Glutamine,
5% HS, 5% FCS, and IL-2 (60 IU /ml). PHA blasts were
irradiated (5,000 Rad) before co-culture with T cells. After 24
h at 37◦C, supernatants were collected and frozen until further
use. IFNγ levels were measured in a standard enzyme-linked
immunosorbent assay (ELISA), according to manufacturer’s
protocol (U-Cytech, Utrecht, the Netherlands). The range of the
ELISA standard curve was 5–5120 pg/ml.
4.4. Cytotoxicity Assays
After 8 days of expansion with allogeneic irradiated PBMC,
serial dilutions of responder CD8+ T cell lines and clones
were incubated with 51Chromium-labeled EBV-LCLs, SALs
and/or 721.221 target cells, PHA blasts and HUVECs
(responder/stimulator ratio 30:1; 10:1; 1:1; 0.1:1) in round-
bottom 96-wells plates for 4 or 20 h at 37◦C in IMDM
supplemented with Pen/Strep, L-Glutamine, 5% HS, 5% FCS,
and IL-2 (60 IU/ml). Where applicable, viral peptide was loaded
onto the target cells for 60 min at 37◦C, simultaneously with
chromium incubation, and washed thrice. In addition, CD8+ T
cell lines and clones were incubated with the anti-CD8 blocking
antibody FK18 (4.3 µl/ml) for 60 min at 37◦C, where after cells
were washed twice. Supernatants were harvested for analysis
on a gamma-counter (PerkinElmer 2470 Wizard2, Waltham,
MA), counts from triplicate wells were averaged, and specific
lysis was calculated as follows: (Condition of interest 51Cr
release − Spontaneous 51Cr release)/(Maximum 51Cr release
− Spontaneous 51Cr release) x 100. Maximum 51Cr release of
the target cells was determined in PBS 1% Triton X-100 and
spontaneous 51Cr release in medium.
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